Skip to main content
Figure 5 | Retrovirology

Figure 5

From: HIV-1 Tat second exon limits the extent of Tat-mediated modulation of interferon-stimulated genes in antigen presenting cells

Figure 5

Tat modulation of ISG requires P-TEFb and Sp1. A. Luciferase activity in THP-Mac lysates expressing the wild-type TatSF2, the single exon TatSF21-72, TatSF2C25,30,34S or TatSF2K28,50A and transfected with IRF7-, MAP2K6-, or MAP2K3-luciferase reporter vectors (the promoter used in the transfected vector is indicated above the bars). Significantly different levels of luciferase activity could be detected between TatSF2 and TatSF21-72 for all three promoters (MAP2K3: p = 0.04; MAP2K6: p = 0.03; IRF7: p = 0.004, T Test). B. Luciferase activity in lysates from THP-Mac expressing the wild-type TatSF2, the single exon TatSF21-72 and transfected with MAP2K3-, MAP2K6-, or IRF7-luciferase reporter vectors. “ + Fvp” indicates treatment with Flavopiridol (70 nM). C. Luciferase activity in lysates from THP-Mac expressing the wild-type TatSF2 or TatSF21-72 and transfected with MAP2K3, MAP2K6-, or IRF7-luciferase reporter vectors in the presence or absence of WP631, a Sp1 inhibitor. “ + WP” indicates treatment with WP631 (0.3 ug/ml). D, E. Western Blot of Tat expressing cells at 8 and 16 h post infection, treated or not treated with Flavopiridol (D) or with WP631 (E). Dotted lines indicate pairs of values with statistically significant differences.

Back to article page